reason report
soft portend worsen growth dead money
bottom line earn miss weak revenu guidanc
continu rate abbvi share market perform abbvi
major product humira revenu guid declin
almost entir off-set growth recent emerg
drug launch result nearli flat revenu reduc
revenu forecast start earn forecast
reduc price target base
chang decreas peer multipl slow growth
adjust estim recent consensu revenu
lower later year ep estim
line consensu near term longer term
notabl deni suggest approach ceo
transit also made clear contempl
larg merger acquisit
morn report small revenu miss
ep miss versu consensu announc ep guidanc
bracket consensu miss driven lower-than-
expect humira sale steep declin androgel due gener
competit higher cog off-set strength
hcv sale lower tax rate share repurchas balanc
growth product new launch fail off-set declin legaci
product face gener biosimilar competit like persist
appear like report peer-worst top-
line growth profil year manag commentari
guidanc expect biosimilar eros ex-u humira worsen
compar previou estim
second time ex-u humira eros guidanc
chang result fulli discret abbvi
manag fluctuat public announc expect
cast doubt reliabl manag famou
guidanc call still reiter confid target
total sale though admit
contribut product vari origin expect
abbvi remain earn report view bound
tens investor receiv flat top-lin bottom-lin growth
boost share repurchas wait shoe drop
net debt total capit
price-to-earnings lt ep growth
averag dcf price-to-earnings p/sale
year price history/av daili volume mil
compani inform svb leerink llc research
revenu mm dilut ep includ option expens present
pleas refer page import disclosur price chart analyst certif
price target per share stock rate market perform
transit corpor ownership success larg independ
biopharmaceut compani mani best featur biotech pharma
resourc expertis infrastructur diversif larg pharma competitor
specialti product profil matur biotechnolog compani remain highli depend
singl franchis humira sale total sale suggest
us valuat still discount compar diversifi peer
multipl settlement us biosimilar entrant postpon eros brand domest
eros europ underway appear sharper faster prior
product abbvi abil control destini may fade depend action
new entrant even us would surpris see pressur humira
growth new entrant chang regul legal oversight manag care
pbm contract still expect oncolog product imbruvica venclexta becom
signific product gener revenu
compani hcv product maintain roughli pariti share competitor
look compani array promis late-stag clinic medicin
inflamm metabol diseas struggl expand oncolog franchis beyond
imbruvica venclexta year flat forecast revenu growth current
pipelin establish product contribut singl digit revenu growth
unlik off-set massiv headwind face biosimilar enter market
compet humira
imbruvica hcv strength could off-set weaker humira top-lin miss
abbvi total product revenu consensu
line estim global humira sale sequenti
consensu forecast us humira revenu
grew y/i high single-digit volum small price contribut
consensu forecast meanwhil ex-u humira revenu declin
q/q miss consensu estim us imbruvica sale grew
sequenti consensu forecast
abbvi row profit share imbruvica grew q/q
consensu hcv revenu quarter viekira mavyret declin us
grew ex-u sequenti us hcv revenu decreas sequenti
came consensu estim expect row hcv revenu
increas sequenti came consensu estim
expect product sale mostli weak quarter
signific consensu miss androgel sevofluran
higher expens contribut ep miss total non-gaap expens
consensu estim driven primarili higher product
sell cost result oper margin steep declin
higher abbvi tax rate percentag point
lower expect share count consensu expect
decreas enough beat consensu ep result report non-gaap ep
annual growth consensu estim
multipl revenu headwind forecast explicitli guid total revenu
achiev oper growth expect entir wash
fx headwind reason sluggish three-fold first humira expect
declin eros ex-u market due biosimilar competit outweigh
expect growth us amount y/i eros ex-u humira sale
first full year biosimilar competit importantli estim contempl increment
decreas price power compar today manag chose conserv approach
price still evolv certain southern european countri germani said
continu insist percent declin humira sale due biosimilar moder
take anoth step new market open biosimilar
howev previous point annual sale declin steepen
subsequ year histor anti-tnf analogu biosimilar competit exampl
annual eros rate remicad first second third
second androgel product expect declin due
launch gener competitor third hcv busi switch grow
flat best
unveil guidanc bracket consensu unveil guidanc
first time friday expect adjust ep rang
compar consensu updat estim compani also provid
detail product guidanc outlin exhibit
guidanc import revenu guidanc humira imbruvica
expect us humira sale grow full-year consensu
line updat estim ex-u revenu expect declin full-year
repres sale eros consensu line
updat estim final expect us imbruvica sale grow full-year
line consensu updat estim
catalyst includ two wide anticip drug launch multipl potenti label
expans opportun hematology-oncolog catalyst flow larg
includ known product alreadi nearli fulli includ consensu new
immunolog asset slate approv first risankizumab psoriasi
pdufa date april second oral inhibitor upadacitinib rheumatoid arthriti
undisclos pdufa date like fda advisori committe
emphas prefer dose upadacitinib perhap presag
fda label limit lower two dose studi trial compani still suggest
higher dose could approv indic increment efficaci
signific
new drug could emerg anti-egfr epiderm growth factor receptor
antibodi drug conjug depatuxizumab mafodotin phase result
newly-diagnos glioblastoma multiform gbm sometim also report
multipl phase result potenti label expans opportun venclexta throughout
undisclos date includ bellini trial relapsed/refractori multipl myeloma two
frontlin acut myeloid leukemia aml studi trial frontlin chronic
lymphocyt leukemia cll announc data select fda
real-tim oncolog review program could expedit approv process
upadacitinib safeti profil may wood yet one major issu upadacitinib
profil rate venou thromboembol event vte known potenti toxic
jak inhibit releas final phase data upadacitinib
rheumatoid arthriti well fda willing approv baricitinib ra despit
imbal vte conclud upadacitinib profil suffici fda approv see
note final upadacitinib phase clear vte risk hurdl fda persuad
howev recent disclosur lower dose dose
test would propos potenti ra label could reignit investor controversi
product profil accord data clinic trial
dose submit fda draft/propos label dose
repres best dose ra indic accord inde one
import head-to-head studi humira select-comapr dose
test beat humira diseas score test though maintain dose
provid meaning efficaci benefit dose nearli trial
dose result numer higher american colleg rheumatolog
respons score commit studi higher dose upadacitinib
indic atop dermat may increment benefit gain
believ strong chanc fda advisori committe meet ra indic
addit upadacitinib data disclos could caus volatil stock
model updat reduc humira imbruvica estim pt follow result
guidanc revis revenu earn forecast better reflect
compani outlook decreas forecast humira
reflect faster ex-u price eros also decreas revenu
imbruvica given conserv guidanc despit strong volum sale trend
forecast hcv increas reduc
biggest chang androgel estim decreas due earli
rate gener competit also made neg chang kaletra sevofluran
increas creon futur period total revenu forecast
decreas updat total revenu forecast
consensu consensu new forecast
total revenu grow modestli recent consensu
well manag prior guidanc continu forecast
oper margin reduc percentag point estim margin
forecast still assum signific growth
decreas estim due larg reduct share count pro-forma dilut
ep forecast higher reduc
line consensu pro-forma dilut ep
consensu net result adjust chang sector valuat
multipl bring target price previous
price target base simpl averag three approach
believ reason basi valu stock today approach simpl price
earn multipl compar larg biopharmaceut compani price sale multipl
larg cap peer compani stock discount cash flow dcf appli peer ep
revenu multipl use averag larg cap larg molecul therapeut compani mid-
term growth tail risk celg averag consensu ep
multipl appli current ep estim give valu
use revenu multipl similar compani consensu
sale appli revenu estim give valu
lastli dcf valuat given wacc termin cash flow growth rate
begin humira biosimilar entri give present valu averag
three method current price target
risk view outlook valuat includ major chang price
outlook reimburs coverag label competit posit humira compani
main product risk includ commerci develop disappoint compani
follow-on program inflammatori diseas imbruvica venclexta expand
hematolog malign well competit posit compani next-
gener hcv therapi assum oper margin stabil around
acceler revenu eros could neg affect margin outlook
compani remain highli lever commit grow dividend reduct
forecast ebitda due neg busi trend would place compani capit alloc
strategi dividend growth risk opportun upsid expect includ
stronger-than-expect price volum share humira emerg tangibl
demand underappreci element compani early-to-mid stage pipelin asset
potenti label expans opportun late stage opportun
non-gaap cost good sold
interest expens
abbvi guidanc
svb leerink llc research compani file zack factset consensu
svb leerink llc research compani file zack factset consensu
late stage pipelin program includ
late stage pipelin program exclud
bispecif mab i/o rova-t non-rova-t
million
svb leerink llc research compani file
million
good sold
 total revenu
sg total revenu
svb leerink llc research compani file
brand chemic name
type event
event trial detail
date known
specifi
up/down
leerink view event
phase trial reuslt newly-diagnos
cll trial front-lin cll
supplementari approv cll result front-
bellini trial relapsed/refractori multipl
phase trial front-lin aml
svb leerink llc research compani file
analysi stock price svb leerink target
method price base current larg cap hc stock mid-term growth tail risk
ep multipl appli ep celg
svb leerink forma ep estim
method present valu base price sale multipl peer larg cap biopharma stock
averag price sale larg cap biopharma multipl
impli market cap mm estimate sale
anticip share count mm
method leerink probabl adjust dcf adjust net wacc termin
current svb leerink dcf marketed/l stage program
sourc svb leerink llc estim compani file factset
